Outcome of Board Meeting
AMBALALSA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The Board approved audited financial results for Q4 and FY ended March 2026. Consolidated revenue grew modestly by 3.1% to Rs 20,227 Lakhs from Rs 19,619 Lakhs. However, profit after tax surged dramatically to Rs 1,780 Lakhs from Rs 93 Lakhs - a 1,811% increase. EPS improved to Rs 2.32 from Rs 0.64. The jump in profitability was partly due to reversal of provisions no longer required and lower exceptional losses (Rs 82 Lakhs vs Rs 700 Lakhs previously). Pharmaceuticals segment contributed Rs 11,051 Lakhs and Electronics Rs 9,178 Lakhs to revenues. The statutory auditors issued unqualified opinions on both standalone and consolidated results. The Board also approved inter-corporate loans to three group companies (Asence Pharma, Synbiotics, Systronics India) and recommended re-appointment of key directors.
The massive PAT growth is positive for shareholders but the modest revenue growth (3.1%) suggests profitability gains came mainly from one-time provisions rather than core business expansion. The unqualified audit opinion provides comfort on financial reporting quality.